Phase 1/2 × OTHER × Alemtuzumab × Clear all
NCT02061800 2024-06-04

CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell Transplant

Columbia University

Phase 1/2 Active not recruiting
14 enrolled
NCT00085449 2019-11-27

Alemtuzumab Plus Fludarabine and Melphalan With or Without Cyclosporine, Mycophenolate Mofetil, and Low-Dose Total-Body Irradiation Therapy Followed by Donor Peripheral Stem Cell Transplant in Treating Patients With Hematologic Cancer

Alliance for Clinical Trials in Oncology

Phase 1/2 Withdrawn
NCT00056966 2012-06-29

Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases

Baylor College of Medicine

Phase 1/2 Completed
24 enrolled